Page 100 - Read Online

D’Amico et al. J Cancer Metastasis Treat 2021;7:3 I http://dx.doi.org/10.20517/2394-4722.2020.93 Page 15 of 16

personalized circulating tumor DNA analysis. Sci Transl Med 2019;7392:1-14.
33. Krishnamurthy S, Cristofanilli M, Singh B, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast
cancer. Cancer 2010;116:3330-7.
34. Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry A 2007;71:154-62.
35. Xenidis N, Perraki M, Kafousi M, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected
by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006;24:3756-62.
36. Rack B, Schindlbeck C, Jückstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J
Natl Cancer Inst 2014;106:dju066.
37. Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy
in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008;14:7004-10.
38. Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. The Lancet Oncology
2012;13:688-95.
39. Pierga JY, Petit T, Lévy C, et al. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast
cancer patients with excellent prognosis: BEVERLY-2 survival data. Clin Cancer Res 2015;21:1298-304.
40. Pierga JY, Bidard FC, Autret A, et al. Circulating tumour cells and pathological complete response: independent prognostic factors in
inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy
combined with bevacizumab. Ann Oncol 2017;28:103-9.
41. Riethdorf S, Müller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer
patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010;16:2634-45.
42. Trapp E, Janni W, Schindlbeck C, et al. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and
prognosis. J Natl Cancer Inst 2019;111:380-7.
43. Sparano JA, Henry NL. Surveillance after treatment of localized breast cancer: time for reappraisal? J Natl Cancer Inst 2019;111:339-41.
44. Bidard FC, Mathiot C, Delaloge S, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann
Oncol 2010;21:729-33.
45. Azim HA Jr, Rothé F, Aura CM, et al. Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-
study from the NeoALTTO phase III trial. Breast 2013;22:1060-5.
46. Bidard FC, Jacot W, Kiavue N, et al. Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice
in hormone receptor-positive, ERBB2-negative metastatic breast cancer: the STIC CTC randomized clinical trial. JAMA Oncol
2020;5:e205660.
47. Bauer ECA, Schochter F, Widschwendter P, et al. Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after
adjuvant treatment. Breast Cancer Res Treat 2018;171:571-80.
48. Hall C, Karhade M, Laubacher B, et al. Circulating tumor cells after neoadjuvant chemotherapy in stage I-III triple-negative breast cancer.
Ann Surg Oncol 2015;22:S552-8.
49. Janni WJ, Rack B, Terstappen LW, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer.
Clin Cancer Res 2016;22:2583-93.
50. Bidard FC, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-
analysis. J Natl Cancer Inst 2018;110:560-7.
51. Davis AA, Jacob S, Gerratana L, et al. Abstract P5-01-08: landscape of circulating tumor DNA (ctDNA) in metastatic breast cancer.
Cancer Res 2020;80:P5-01-08.
52. Paweletz CP, Lau CJ, Oxnard GR. Does testing error underlie liquid biopsy discordance? JCO Precision Oncology 2019;3:1-3.
53. Gerratana L, Zhang Q, Shah AN, et al. Performance of a novel next generation sequencing circulating tumor DNA (ctDNA) platform for
the evaluation of samples from patients with metastatic breast cancer (MBC). Crit Rev Oncol Hematol 2020;145:102856.
54. Serpas L, Chan RWY, Jiang P, et al. Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proc Natl
Acad Sci U S A 2019;116:641-9.
55. Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med
2018;10:eaat4921.
56. Liu L, Toung JM, Jassowicz AF, et al. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.
Ann Oncol 2018;29:1445-53.
57. Gerratana L, Basile D, Franzoni A, et al. Plasma-based longitudinal evaluation of ESR1 epigenetic status in hormone receptor-positive
HER2-negative metastatic breast cancer. Front Oncol 2020;10:550185.
58. Maltoni R, Casadio V, Ravaioli S, et al. Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast
cancer. Oncotarget 2017;8:16642-9.
59. Yizhak K, Aguet F, Kim J, et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues expansion
across normal tissues. Science 2019;364:eaaw0726.
60. Hu Y, Ulrich BC, Supplee J, et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res 2018;24:4437-43.
61. Swanton C, Venn O, Aravanis A, et al. Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-
sensitive sequencing assay: exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study. J Clin Oncol 2018;36:12003.
62. Heuser M, Thol F, Ganser A. Clonal hematopoiesis of indeterminate potential. Dtsch Arztebl Int 2016;113:317-22.
63. Diehl F, Li M, He YP, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil
emulsions. Nat Methods 2006;3:551-9.